News from wuxi biologics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 02, 2020, 06:00 ET Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation

Tubulis, WuXi STA and WuXi Biologics today announced a strategic collaboration to manufacture and advance Tubulis' next generation antibody-drug...


Nov 20, 2020, 03:30 ET WuXi Biologics Launched Biologics Integrated Innovation Center in Hangzhou

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced its biologics...


Oct 29, 2020, 05:00 ET WuXi Biologics and AB2 Bio Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and AB2 Bio Ltd., a Swiss advanced...


Aug 17, 2020, 11:32 ET WuXi Biologics Records Excellent Interim Results

Revenue Up 21.0% Y-o-Y to RMB1,944.1 Million Net Profit Up 62.6% to RMB730.7 Million Profit Attributable to Owners of the Company Up 63.6% Y-o-Y to...


Aug 06, 2020, 05:00 ET WuXi Vaccines Appoints Mr. Jian Dong as Chief Executive Officer

WuXi Vaccines, a global leading company with world-class vaccine contract development and manufacturing organization (CDMO) capabilities, is pleased...


Aug 04, 2020, 05:00 ET WuXi Biologics Awarded as "Most Honored Company" by Institutional Investor

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it was awarded as...


Jun 19, 2020, 05:52 ET Embrace Change to Turn Challenges into Opportunities: WuXi Biologics Successfully Hosted the 2nd Investor Day

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that its 2nd Investor Day...


Jun 15, 2020, 20:00 ET WuXi Biologics (Suzhou) Received EMA GMP Certificate for Biosafety Testing

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that its facility in...


Jun 08, 2020, 20:00 ET WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has signed a...


May 27, 2020, 20:00 ET WuXi Biologics Sweeps 2020 CMO Leadership Awards in All Six Categories

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has been...


May 18, 2020, 20:00 ET WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in the United States

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and the Worcester Business...


Apr 30, 2020, 07:00 ET WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and Aravive, Inc. (NASDAQ:ARAV), a...


Apr 27, 2020, 20:00 ET WuXi Biologics Successfully Completes PFS Filling at its Robotic Aseptic Filling Facility

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that its robotic aseptic...


Apr 21, 2020, 20:00 ET WuXi Biologics Completed Acquisition of a Drug Product Manufacturing Facility in Germany

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed the...


Apr 13, 2020, 20:00 ET WuXi Biologics (Suzhou) Successfully Passed First EMA GMP Inspection

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platform, announced that WuXi Biologics...


Mar 26, 2020, 09:32 ET WuXi Biologics Achieved Remarkable Results in 2019

57.2% Revenue Growth to RMB3,983.7 Million 63.0% Gross Profit Growth to RMB1,658.8 Million Adjusted Net Profit Up 60.3% to RMB1,205.0 Million Diluted ...


Mar 10, 2020, 20:00 ET WuXi Biologics Completes Weather-Tight Seal of its Biologics Manufacturing Facility in Ireland

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


Feb 25, 2020, 08:30 ET WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


Feb 23, 2020, 19:00 ET WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


Feb 18, 2020, 05:42 ET WuXi Biologics' Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


Feb 18, 2020, 05:11 ET WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader

WuXi Vaccines, a new vaccine Contract Development and Manufacturing Organization (CDMO) established between WuXi Biologics (stock code: 2269.HK) and...


Feb 11, 2020, 19:00 ET WuXi Biologics Provides Back-to-work Operation Update Related to the Coronavirus Outbreak

WuXi Biologics is closely monitoring the coronavirus outbreak. Our management team is working vigilantly to execute our Business Continuity Plan to...


Jan 28, 2020, 21:19 ET WuXi Biologics Provides Operation Update Related to the Coronavirus Outbreak

The coronavirus outbreak is having a potentially significant social and economic impact in China. WuXi Biologics is closely monitoring the...


Jan 28, 2020, 20:06 ET WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


Jan 15, 2020, 21:39 ET WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...